Replies to post #32102 on Biotech Values

[DewDiligence]

The idea of developing a “reversible” replacement for a non-reversible blockbuster is not unique to MNTA. For instance, MDCO seeks to dominate antiplatelet use in the cath lab with Cangrelor, which they tout as a short-acting, reversible “Plavix”:

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16504633&...

Dew